← Open Payments lookup

MIRIAM EZENWAKA: Open Payments

NPI 1356061717 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$3,180 in 145 payments from 11 companies in 2025. Trend: 2023 $71 · 2024 $2,301 · 2025 $3,180

Food & beverage: $3,180
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)27$568
E.R. Squibb & Sons, L.L.C.25$448
Alkermes, Inc.21$407
Teva Pharmaceuticals USA, Inc.18$390
Vanda Pharmaceuticals Inc.9$317
Lundbeck LLC14$279
Neurocrine BioSciences, Inc.9$267
Otsuka America Pharmaceutical, Inc.9$202
ABBVIE INC.9$162
Janssen Pharmaceuticals, Inc3$118

Products named: CAPLYTA, COBENFY, ARISTADA, ABILIFY ASIMTUFII, INGREZZA, UZEDY, REXULTI, HETLIOZ.

Industry payments across DC — which companies pay providers there.